©
Shutterstock
Clinical Trials
A key aim of the Department of Oncology is the optimal translation of fundamental research into patient benefit and for Oxford to become the leading centre for translational early-phase oncology trials in the UK.
Read more
Welcome to the The Department of Oncology. The Department of Oncology's mission is to improve cancer care through research and teaching. There is strong emphasis on translation, with established infrastructure to develop scientific insights toward clinical appreciation.
The Department houses over 400 staff and postgraduate students - both clinical and non-clinical - and is one of the largest departments in the University of Oxford's Medical Sciences Division. It is also home to the Institute for Radiation Oncology.
One of the key aims for the Department is to bring together basic scientific and clinical research groups from across Oxford - based in the Old Road Campus Research Building, the Radiobiology Research Institute, the Weatherall Institute for Molecular Medicine and the NHS Cancer and Haematology Centre - to apply knowledge of cancer and to develop research so that we may better understand how we can combat cancer in the most effective way possible.
MRC OXFORD INSTITUTE FOR RADIATION ONCOLOGY
The mission of the MRC Oxford Institute for Radiation Oncology is to explore aspects of radiation biology research that could yield new advances in the treatment of cancer.
DIVISION OF CANCER MEDICINE
The aims of the Division of Cancer Medicine are to understand cancer and the biological processes that govern how it starts, how it behaves and how the body responds to it.
Our News
Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine
5 August 2022
A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.
Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis
29 June 2022
Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.
Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination
24 May 2022
COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
OUH agrees long COVID research collaboration with Polarean
18 May 2022
The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.